Last reviewed · How we verify
IN10018 in combination with PLD — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
IN10018 in combination with PLD (IN10018 in combination with PLD) — InxMed (Shanghai) Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| IN10018 in combination with PLD TARGET | IN10018 in combination with PLD | InxMed (Shanghai) Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- IN10018 in combination with PLD CI watch — RSS
- IN10018 in combination with PLD CI watch — Atom
- IN10018 in combination with PLD CI watch — JSON
- IN10018 in combination with PLD alone — RSS
Cite this brief
Drug Landscape (2026). IN10018 in combination with PLD — Competitive Intelligence Brief. https://druglandscape.com/ci/in10018-in-combination-with-pld. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab